epoetin beta + epoetin beta
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infant, Low Birth Weight
Conditions
Infant, Low Birth Weight, Anemia
Trial Timeline
May 1, 1998 → Jun 1, 1999
NCT ID
NCT00593801About epoetin beta + epoetin beta
epoetin beta + epoetin beta is a pre-clinical stage product being developed by Roche for Infant, Low Birth Weight. The current trial status is completed. This product is registered under clinical trial identifier NCT00593801. Target conditions include Infant, Low Birth Weight, Anemia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00593801 | Pre-clinical | Completed |
Competing Products
20 competing products in Infant, Low Birth Weight
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| somatropin | Eli Lilly | Phase 3 | 77 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| Prevenar (13v) | Pfizer | Pre-clinical | 22 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV | Sanofi | Phase 3 | 76 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 84 |
| Radiprodil | UCB | Phase 2 | 49 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 20 |
| Sabril® | Lundbeck | Pre-clinical | 20 |
| Vigabatrin | Lundbeck | Approved | 82 |
| Nusinersen | Biogen | Pre-clinical | 20 |